Love Lifesciences Announces Strategic Partnership for their UniPen

Love Lifesciences has announced a new strategic partnership with Alliance for Pharmacy Compounding (APC) – a leading trade organization.

The partnership will support Love Lifesciences as they bring their flagship product to market, bringing a safe, self-administered injection tool to innovation-first companies. Their product, UniPen, is a versatile safety injection device designed for a wide range of self-administered injectable therapies, including such popular treatments as GLP-1 agonists, testosterone, and other injectables commonly produced by compounding pharmacies.

Love Lifesciences will provide APC member pharmacies access to UniPen at industry-best pricing, said Love, CEO and co-founder of the company alongside Bradley Hopper.

APC was particularly interested in Love Lifesciences’ design as they created an agnostic injection pen. Without any specific purpose in mind, the device has great potential for compounding pharmacies. 

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.